AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02510391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIPA
Description: Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
Study NCT01237054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-NaF PET
Description: The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
Study NCT01237054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Description: An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
Study NCT01237054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-FDG PET/CT
Description: The 18F-FDG injection procedure will be injected and be followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
Study NCT01125163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.
Study NCT01125163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
Study NCT02562378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab and non-pegylated liposomal doxorubicin
Description: 3 Cohorts (3+3 design):~Cohort 1- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2) IV~Cohort 2- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (50 mg/m2) IV~Cohort 3- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (60 mg/m2) IV
Study NCT03233386 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mantente REAL
Description: substance abuse prevention curriculum for adolescents
Study NCT02055963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
Study NCT02055963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
Study NCT02055963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
Study NCT02055963 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
Study NCT03391284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetominophen
Description: INTRAVENOUS
Study NCT03391284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetominophen
Description: INTRAVENOUS
Study NCT03391284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: ORAL
Study NCT03391284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: ORAL
Study NCT01767103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferriprox®
Study NCT03804983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Closed Loop (HCL)
Description: Participants will use Control-IQ with Hybrid Closed Loop (HCL) with their own insulin parameters during the entire two-week study, including the 72-hour ski admission and the at-home study collection times. Parameters will be reduced 20% during the ski admission to adjust for the increased activity.
Study NCT04183478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: K-001 is an antitumor active substance (peptidoglycan) which is prepared from the fermentation product of marine microorganism. K-001 is the Chinese first class new drug and get patent licensing in China, America and Japan.
Study NCT04183478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo which looks the same as K-001 in apparence
Study NCT01284543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Tan EndoGlide to insert donor graft
Description: Using the Tan EndoGlide to insert donor graft into the eye
Study NCT03148847 — intervention group
Intervention type: OTHER
Intervention: Referential's dissemination
Study NCT04571632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions > 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required.
Study NCT01606878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV
Study NCT01217502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management program
Description: Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
Study NCT01217502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self management program
Description: Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
Study NCT01284543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Busin Glide for delivery of the donor graft
Description: Use of the forceps for delivery of the donor graft into the eye
Study NCT03860688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TED + glucose
Description: Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
Study NCT01295125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XenMATRIX mesh
Description: Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
Study NCT01295125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open abdominal ventral hernia repair
Description: Abdominal ventral hernia repair with native tissue
Study NCT00561327 — intervention group
Intervention type: DRUG
Intervention: losartan
Description: Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
Study NCT02511756 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Computed tomography X-ray system
Description: Contrast-enhanced computed tomography of liver metastases
Study NCT03943485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The uterine manipulator which is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We adopted this device in abdominal hysterectomy.
Description: The uterine manipulator is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We hypothesized that adoption of a uterine manipulator would help the surgeon to better identify the colpotomy site by moving the uterus cranially and thus providing better visualization of the colpotomy site.
Study NCT02135198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg AZD7325
Description: A single 2 mg oral dose of AZD7325
Study NCT02135198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 mg AZD7325
Description: A single 2 mg oral dose of AZD7325
Study NCT02135198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg AZD7325
Description: A single 10 mg oral dose of AZD7325
Study NCT02135198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 mg AZD7325
Description: A single 10 mg oral dose of AZD7325
Study NCT02135198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single oral dose
Study NCT02135198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose
Study NCT02085551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy by the Indigo System
Study NCT00647816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride Extended-Release Capsules 160 mg
Description: 160mg, single dose fasting
Study NCT00647816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inderal® LA Capsules 160 mg
Description: 160mg, single dose fasting
Study NCT02327481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopic Surgery
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
Study NCT02327481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Laparoscopic Surgery
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
Study NCT00643253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC and Electronic Prompt
Description: Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
Study NCT01415674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
Study NCT00464464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral therapy
Description: The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
Study NCT01023321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555
Description: single ascending doses, oral solution
Study NCT01606878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01023321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution
Study NCT01023321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555
Description: multiple dose, oral solution, 7 or 14 days
Study NCT01023321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, oral solution, 7 or 14 days
Study NCT01801254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRIDES
Description: Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
Study NCT01801254 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
Study NCT02076841 — intervention group
Intervention type: DEVICE
Intervention: interferon beta-1a
Description: Administered as specified in the treatment arm
Study NCT04883853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild _moderate Ptosis tucking
Description: A modified levator muscle tucking procedure.The level of sutures was determined according to the levator muscle function and the desired eyelid height. The middle (main) suture was taken first at the level of the medial part of the pupil and was tightened to keep the lid height at the superior limbus and the other two sutures (medial and lateral) were then adjusted. A spindle-shaped, horizontal part of the levator aponeurosis (2.5-3 mm wide and 0.5 mm deep) was excised at the site of insertion into the tarsus before tightening the central suture to induce strong fibrosis and adhesion between the tucked levator aponeurosis and the tarsus
Study NCT03257397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: theta-burst stimulation (TBS) using a MagPro X1000
Description: iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
Study NCT03257397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: theta-burst stimulation (TBS) using a MagPro X1000
Description: iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
Study NCT00672009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone 35 mg/m\^2 intravenously over 3 hours every 21 days for 4 cycles.
Study NCT03830606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel,S-1
Description: Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-14, q3w)
Study NCT01155765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 10 mg/day for 15 days
Study NCT01155765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 150 mg/day for 15 days
Study NCT00700765 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
Study NCT02502448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acute normovolemic hemodilution (ANH)
Description: applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
Study NCT02502448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch (HES 130/0.6)
Study NCT03435419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LoopampTM Leishmania Detection Kit
Description: LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection
Study NCT03435419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CL DetectTM Rapid Test
Description: CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection
Study NCT00645086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin extended-release tablets
Description: 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
Study NCT01803542 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
Study NCT01474187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: initial from 50mg/m2/week and increased by 15mg/m2/week
Study NCT01474187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625mg/m2,bid,d1-5,qw
Study NCT01474187 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50Gy for whole pelvis
Study NCT03038139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical exercises
Description: Cervical correction program consist of 3 strengthening and 2 stretching exercises for neck and scapula Lumbosacral correction program consist of strengthening and stretching exercises for lumbar and sacral regions
Study NCT03038139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumosacral exercises
Description: Cervical and Lumbosacral correction program Lumbosacral program consist of 2 strengthening and 4 stretching exercises
Study NCT03673358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT
Study NCT01052415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sessions
Description: Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
Study NCT01139879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P400 mattress
Description: The P400 mattress will be placed for a period of 12 weeks.
Study NCT04498104 — intervention group
Intervention type: OTHER
Intervention: Psychological assessment
Description: Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.
Study NCT04137536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR-bispecific antibody armed activated T-cells
Description: Phase I:~* First 3 participants, twice weekly infusions of 10\^10 EGFR BATs infusions~* If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10\^10.~* If >/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10\^9 per infusion~* If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~- 8 infusions of 7.5 x 10\^9 or 10\^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)
Study NCT00645086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin immediate-release tablets
Description: 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
Study NCT00303043 — intervention group
Intervention type: PROCEDURE
Intervention: Mixed venous saturation monitoring
Description: Mixed venous saturation monitoring
Study NCT00869297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Directed Fluid Administration
Description: Intravenous Fluid will be given if SVV exceeds 13%
Study NCT00869297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Fluids titrated at discretion of anesthesiologist.
Study NCT03373019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with R-GDP
Description: Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
Study NCT00634231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk
Study NCT00634231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Study NCT00634231 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation